344604-91-7

Upstream product

• 391904-95-3 5-[1-[4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-phenyl]-meth-(Z)-ylidene]-thiazolidine-2,4-dione 
• 79421-40-2 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde 
• 349636-48-2 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]thiazolidine-2,4-dione 
• 391904-97-5 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzyl]-thiazolidine-2,4-dione 

Downstream Products

• 349636-91-5 5-(3-amino-(2S)-2-hydroxypropoxy)-8-hydroxy-3,4-dihydro-1H-quinolin-2-one 
• 208459-22-7 (2S)-1-Amino-3-(4-hydroxy-phenoxy)-propan-2-ol 
• 13698-56-1 N-[5-(2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide 
• 391905-31-0 5-[[4-[4-[[(R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl]methyl]-2,4-dioxo-3-thiazolidineacetic acid tert-butyl-ester 
• 349636-61-9 tert-butyl 2-{2,4-dioxo-5-[4-(4-oxo-1-piperidinyl)benzyl]-1,3-thiazolidin-3-yl}acetate 

Relevant academic research and scientific papers

Synthesis of heterocycle substituted 1-aryl-4-piperidones

A series of heterocycle substituted 1-aryl-4-piperidones were prepared via Knoevenagel condensations between nitrogen-containing 5-membered heterocycles and benzaldehyde (1) followed by reduction or amination. The oxadiazolidinedione ring was formed by reacting the N-hydroxyurea (10) with methyl chloroformate and sodium hydride.

New oxadiazolidinedione derivatives as potent and selective human β3 agonists

As part of our investigation into the development of potent and selective human β3 agonists, a series of thiazolidinedione analogues was prepared and evaluated for their biological activity on the human β3-adrenergic receptor. The oxadiazolidinedione derivative 17 was found to be the most potent and selective compound in this study, with an EC50 value of 0.02μM at the β3 receptor, 259-fold selectivity over the β1 receptor, and 745-fold selectivity over the β2 receptor.

2,4-Thiazolidinediones as potent and selective human β3 agonists

Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 μM, IA = 1.19) and selective (more than 110-fold over β1 and β2 agonist activity) β3 agonist. This compound has also been proven to be active and selective in an in vivo mode.